Key Investor Signals
Founders bring a prior exit and national-scale product experience.
Kenneth Lou grew beyond 1.1 million monthly users before its 2018 sale to . Joel Kek was tech lead for Singapore's , used by 90% of the population.
Over one million lab tests run since 2023
Mito Health reported passing one million lab tests in July 2026, with results feeding personalized plans across supplements, exercise, nutrition, and sleep.
Raised $4M, including a $2.2M seed round in March 2025.
Backers include , , Kevin Aluwi of , Prashanth Prakash of , Balaji Srinivasan, and Dhruv Arora.
Other Positive Signals
- Serves all 50 US states through partner laboratories.
- Advised by longevity scientists Brian Kennedy and Matt Kaeberlein.
- Partners with for body-composition scans and for whole-body MRI.
- Offers a catalogue of 1,000+ markers, panels, scans, and at-home kits.
- Added at-home collection with clinician review equivalent to an in-lab draw.
Team
Kenneth Lou
Co-Founder and CEO
- Co-founded Seedly in 2016 and led it as CEO for six years, growing it past 1.1 million monthly users.
- Seedly was acquired by ShopBack in 2018, then by CompareAsia Group in 2020, now listed on Nasdaq as .
- Continued running Seedly inside both acquirers, as Country Head at ShopBack and General Manager at Hyphen Group, until 2022.
- Co-founded hardware startup as CEO in 2013. Its Ampere wireless charging sleeve passed a $60,000 Kickstarter goal in under 24 hours.
Joel Kek
Co-Founder and CTO
- Tech lead for TraceTogether at , used by 90 percent of the population, and author of its privacy-preserving protocol paper.
- Tech lead for MyMoneySense at GovTech, running a team from concept to beta and shaping architecture.
- Built HIPAA-compliant health infrastructure with the Stanford Center for Health Policy, helping village health workers target child nutrition supplements.
- Built early versions of a dementia care product at , combining personalized care plans with predictive analytics.
Dr Ryan Ware
Chief Medical Officer
- Practised as a Medical Officer with Singapore's Ministry of Health for five years, from 2016 to 2021.
- Completed a residency in otorhinolaryngology at and a Masters of Medicine in the specialty in 2022.
- Elected a Member of the in 2019.
- Instructed more than 150 registered doctors in trauma and emergency care for the .
Product
Mito Health is a direct-to-consumer platform offering lab tests, medical scans and at-home kits. Customers can order individual tests or personalized panels, while members receive at-cost pricing and ongoing guidance based on their results.
Personalized test selection
A free questionnaire recommends which tests match the customer's goals and which can be skipped. Customers can also browse the catalogue or refine their selection through Mito Concierge.
At-cost testing through membership
Tests can be ordered without a membership at standard prices. For $9 per month, members pay Mito Health's cost on labs and scans, while the company earns its revenue from membership rather than test margins.
Clinician-reviewed guidance
Every order is reviewed and signed by a physician in Mito Health's network. Results feed a personalized action plan, longitudinal tracking and AI-supported guidance, with clinician consultations available when needed.
Market Overview
Preventive testing can identify metabolic and cardiovascular risks before symptoms appear, yet access remains uneven. The United States has 115.2 million adults with , and 80% are unaware of it. More broadly, 92% of adults aged 35 and over do not receive all recommended high-priority preventive services.
Consumers are increasingly purchasing tests outside insurance-funded care and annual physicals. The global market was valued at $4.7 billion in 2025 and is projected to reach $16.1 billion by 2033. Individual consumers already account for 57.3% of category revenue.
More than two in five adults, with 80% unaware of their condition.
Share of US adults aged 35 and over who miss at least one recommended high-priority preventive service.
Share of direct-to-consumer testing revenue paid by individual consumers.
Projected global market growth from 2025 to 2033.
Comparable Outcomes
Thorne HealthTech
Thorne combined at-home biomarker testing with supplements and personalized recommendations based on results. Thorne went public in 2021 at $10 a share, valuing it at about $525 million. acquired the company in 2023 for $10.20 a share in cash, valuing the transaction at about $680 million.
Ancestry
scaled direct-to-consumer DNA testing and added subscription revenue for continued access to results and research tools. acquired it in 2020 at a $4.7 billion enterprise value. Ancestry had more than 3.6 million paying subscribers at the time.
One Medical
charged a membership fee for primary care, combining in-office visits, on-site labs and round-the-clock virtual care. One Medical went public in 2020 at $14 a share, valuing it at about $1.7 billion. Amazon acquired the company in 2023 for $18 a share in cash, valuing the transaction at about $3.9 billion
Have a question about Mito Health?
Ask DealBio. We may research the answer or share selected questions with the company.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.